science

Sugemalimab

Sugemalimab is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Sugemalimab rather than just read about it. In short: Sugemalimab, sold under the brand name Cejemly among others, is a monoclonal antibody used for the treatment of metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy. It is an antineoplastic monoclonal antibody that potentiates T-cell responses, including anti-tumor responses, through blockade of PD-1 binding to PD-L1 ligands.

Key takeaways

Sugemalimab belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Sugemalimab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Sugemalimab from memory before moving on to harder problems.

Reference excerpt

Sugemalimab, sold under the brand name Cejemly among others, is a monoclonal antibody used for the treatment of metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy. It is an antineoplastic monoclonal antibody that potentiates T-cell responses, including anti-tumor responses, through blockade of PD-1 binding to PD-L1 ligands. The most common side effects include anemia (low red blood cells), increased levels of aminotransferases (liver enzymes), rash, hyperlipidemia (high blood fat levels), hyperglycemia (high blood glucose levels), hyponatremia (low blood levels of sodium), hypokalemia (low blood levels of potassium), proteinuria (protein in urine), abdominal (belly) pain, tiredness, arthralgia (joint pain), hypoesthesia (reduced sensation to touch, pain and temperature), hypothyroidism (underactive thyroid gland) and hypocalcemia (low blood levels of calcium). Sugemalimab was approved for medical use in China in December 2021, the European Union in July 2024, and the United Kingdom in October 2024.

Medical uses Sugemalimab, in combination with platinum-based chemotherapy, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer with no sensitising EGFR mutations, or ALK, ROS1 or RET genomic tumor aberrations.

Mechanism of action Sugemalimab is a fully human monoclonal antibody that targets the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and possesses immune checkpoint inhibitory and antineoplastic properties. When administered, sugemalimab binds specifically to PD-L1, blocking its interaction with its receptor, programmed cell death 1 (PD-1). This inhibition reverses T-cell inactivation induced by PD-1/PD-L1 signaling, enhancing the cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells that express PD-L1. Many types of human cancer cells overexpress PD-L1, which, when bound to PD-1 on T-cells, suppresses the immune system and enables immune evasion. PD-1 itself is a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, acting as a negative immune regulator that limits CD8-positive T-cell expansion and survival. The anti-PD-L1 monoclonal antibody CS1001, modeled after natural immunoglobulin G4 (IgG4), may reduce immunogenicity and other associated toxicities.

Society and culture

Legal status In May 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Cejemly, intended for the first-line treatment of metastatic non-small cell lung cancer in combination with chemotherapy. The applicant for this medicinal product is SFL Pharmaceuticals Deutschland GmbH. Sugemalimab was authorized for medical use in the European Union in July 2024. In October 2024, the UK's Medicines and Healthcare products Regulatory Agency approved sugemalimab as part of a first-line combination treatment for lung cancer. The approval was granted to CStone Pharmaceuticalsn under brand name Eqjubi. Approval was based on the findings from the multicenter, randomized, double-blind phase III GEMSTONE-302 trial (NCT03789604).

Names Sugemalimab is the international nonproprietary name.

References

Worked examples

Example 1 — a first encounter with Sugemalimab

Start with the simplest possible case. Write down what Sugemalimab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Sugemalimab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Sugemalimab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Sugemalimab

In research: Sugemalimab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Sugemalimab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Sugemalimab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Cancer treatments, Monoclonal antibodies for tumors, Orphan drugs, so understanding it makes those chapters shorter.
In everyday life: Look for Sugemalimab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Sugemalimab” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Sugemalimab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Sugemalimab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Sugemalimab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Sugemalimab in simple terms?

Why does Sugemalimab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Sugemalimab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Sugemalimab.